Press release
High Grade-Glioma Pipeline Outlook Report 2025: Exploring Breakthrough Drugs and Emerging Therapies | DelveInsight
Explore our latest breakthroughs in High-Grade Glioma Research. Learn more about our innovative pipeline today! @ High-Grade Glioma Pipeline Outlook [https://www.delveinsight.com/sample-request/high-grade-glioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the High-Grade Glioma Pipeline Report
* On 16 October 2025, Eli Lilly and Company conducted a Phase 2 Study Evaluating Abemaciclib in Combination With Temozolomide Compared to Temozolomide Monotherapy in Children and Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy.
* DelveInsight's High-Grade Glioma pipeline report depicts a robust space with 150+ active players working to develop 150+ pipeline therapies for High-Grade Glioma treatment.
* The leading High-Grade Glioma Companies such as Mateon Therapeutics, BioMimetix, Oblato, Inc, PTC Therapeutics, Lee's Pharmaceutical Limited, Nuvation Bio, Inc., Laminar Pharmaceuticals, Basilea Pharmaceutica, Aadi, LLC, Erimos Pharmaceuticals and others.
* Promising High-Grade Glioma Pipeline Therapies such as Lomustine, Temozolomide, Depatuxizumab mafodotin, etoposide, cyclophosphamide, celecoxib, Karenitecin (BNP1350), Bevacizumab and Erlotinib, Gliolan, Dostarlimab and others.
Stay informed about the cutting-edge advancements in High-Grade Glioma treatments. Download for updates and be a part of the revolution in immunotherapy Care @ High-Grade Glioma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/high-grade-glioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
High-Grade Glioma Overview
A glioma is a name for tumours of the glial cells. These are the supporting cells of the nervous system. Gliomas can arise in any part of the brain and may also be found in the spinal cord. More than half of all brain tumours in children are gliomas. There are different types of gliomas. Physicians use the terms "glioma" and "astrocytoma" interchangeably.
High-Grade Glioma Emerging Drugs Profile
* OT101: Mateon Therapeutics
OT101, a first-in-class RNA therapeutic, is designed to abrogate the immunosuppressive actions of TGF-beta 2. In a completed Phase II clinical study, OT-101 exhibited clinically meaningful single-agent activity and induced durable complete and partial responses in recurrent and refractory adult High-Grade Glioma patients, including adults with GBM. Further development of OT-101 may offer renewed hope for salvage therapy of pediatric DIPG patients who have this rare and fatal disease.
* BMX-001: BioMimetix
BMX-001 is being studied in a phase II randomized trial studying the safety and efficacy of the investigational drug in patients with newly diagnosed High-Grade Glioma patients who are being treated with brain radiation and temozolomide.
* OKN-007: Oblato, Inc.
OKN-007 is being developed by Oblato, Inc for the treatment of High-Grade Glioma. It is currently in phase I/II stage of development.
* PTC596: PTC Therapeutics
PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. PTC596 acts by altering and destroying the BMI1 protein through a process called phosphorylation. PTC596 has potently inhibited BMI1 function in multiple tumor cell lines. In in vitro tests, PTC596 has preferentially targeted chemotherapy resistant cancer stem cells. Specifically, PTC596 preferentially depleted cancer stem cells in assays with tumor cell lines from fibrosarcoma, prostate and colon cancers. Conversely, the cytotoxic chemotherapies carboplatin, temozolomide, methotrexate and indibulin enriched the population of cancer stem cells in this assay. It is currently in phase I stage of development.
The High-Grade Glioma Pipeline Report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of High-Grade Glioma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for High-Grade Glioma Treatment.
* High-Grade Glioma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* High-Grade Glioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the High-Grade Glioma market.
Learn more about High-Grade Glioma Drugs opportunities in our groundbreaking High-Grade Glioma research and development projects @ High-Grade Glioma Unmet Needs [https://www.delveinsight.com/sample-request/high-grade-glioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
High-Grade Glioma Companies
Mateon Therapeutics, BioMimetix, Oblato, Inc, PTC Therapeutics, Lee's Pharmaceutical Limited, Nuvation Bio, Inc., Laminar Pharmaceuticals, Basilea Pharmaceutica, Aadi, LLC, Erimos Pharmaceuticals and others.
High-Grade Glioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Infusion
* Intradermal
* Intramuscular
* Intranasal
* Intravenous
* Oral
* Parenteral
* Subcutaneous
* Molecule Type
High-Grade Glioma Products have been categorized under various Molecule types such as
* Gene therapies
* Small molecule
* Vaccines
* Polymers
* Peptides
* Monoclonal antibodies
* Product Type
Discover the latest advancements in High-Grade Glioma treatment by visiting our website. Stay informed about how we're transforming the future of Immunotherapy @ High-Grade Glioma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/high-grade-glioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the High-Grade Glioma Pipeline Report
* Coverage- Global
* High-Grade Glioma Companies- Mateon Therapeutics, BioMimetix, Oblato, Inc, PTC Therapeutics, Lee's Pharmaceutical Limited, Nuvation Bio, Inc., Laminar Pharmaceuticals, Basilea Pharmaceutica, Aadi, LLC, Erimos Pharmaceuticals and others.
* High-Grade Glioma Pipeline Therapies- Lomustine, Temozolomide, Depatuxizumab mafodotin, etoposide, cyclophosphamide, celecoxib, Karenitecin (BNP1350), Bevacizumab and Erlotinib, Gliolan, Dostarlimab and others.
* High-Grade Glioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* High-Grade Glioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of High-Grade Glioma Pipeline on our website @ High-Grade Glioma Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/high-grade-glioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* High-Grade Glioma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* High-Grade Glioma - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* High-Grade Glioma Collaboration Deals
* Late Stage Products (Phase III)
* OT101: Mateon Therapeutics
* Mid Stage Products (Phase II and Phase I/II)
* BMX-001: BioMimetix
* OKN-007: Oblato, Inc.
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* PTC596: PTC Therapeutics
* Pre-clinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* High-Grade Glioma Key Companies
* High-Grade Glioma Key Products
* High-Grade Glioma- Unmet Needs
* High-Grade Glioma- Market Drivers and Barriers
* High-Grade Glioma- Future Perspectives and Conclusion
* High-Grade Glioma Analyst Views
* High-Grade Glioma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=high-gradeglioma-pipeline-outlook-report-2025-exploring-breakthrough-drugs-and-emerging-therapies-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/high-grade-glioma-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release High Grade-Glioma Pipeline Outlook Report 2025: Exploring Breakthrough Drugs and Emerging Therapies | DelveInsight here
News-ID: 4241442 • Views: …
More Releases from ABNewswire
Chicago Divorce Lawyer Russell D. Knight Addresses Guns, Firearms, And Divorce I …
Chicago, Illinois - Chicago divorce lawyer Russell D. Knight of The Law Office of Russell D. Knight (https://rdklegal.com/guns-firearms-and-divorce-in-illinois) is providing detailed guidance on how guns and other firearms are treated in Illinois divorce cases, including their classification as marital or non-marital property, the impact of Firearm Owner's Identification (FOID) requirements, and the effect of orders of protection on firearm ownership. His recent educational efforts aim to help divorcing spouses understand…
Why Every New York City Building Needs Proper Access Control
Image: https://www.abnewswire.com/upload/2025/12/08b54fc2933f1d71e2bd75a4438668ad.jpg
New York City is fast, crowded, and always moving - and that's exactly why every building here depends on strong security. Whether it's an apartment, office, retail store, or commercial tower, the first thing people look for is safety. And in a city this busy, basic locks simply aren't enough anymore. This is why many property owners now rely on advanced systems, expert guidance, and professional locksmith services in…
DPDP Act Sparks Urgent Overhaul of Consent and Data Workflows in Indian Healthca …
Understand DPDP compliance for legal and healthcare teams in India. Learn key risks, workflow fixes, and how Certinal ensures secure, compliant consent.
India's Digital Personal Data Protection (DPDP) Act, 2023 marks a pivotal shift in how organizations are expected to collect, store, and process personal data. For legal and healthcare professionals in particular, DPDP compliance is no longer just a regulatory obligation - it is now central to operational risk, patient…
Repenic Unveils Stylish Dimmer Switches to Elevate UK Homes
Repenic [https://www.repenic.com/], the UK-based smart home technology brand, has launched a new range of dimmer switches designed to combine sophisticated design with advanced functionality. This launch marks a significant step in Repenic's strategy to strengthen its presence in the UK market by offering homeowners products that are both practical and visually striking.
The UK housing market is increasingly embracing home automation, yet many homeowners face challenges finding dimmer switches that work…
More Releases for Glioma
Glioma Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Glioma Pipeline Insight 2024" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the Glioma pipeline landscape. It covers the Glioma Pipeline Drug profiles, including clinical and nonclinical stage products. It also covers the Glioma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request a sample and discover the recent advances…
Glioma Competitive Landscape 2023 (Updated)
DelveInsight's, "Glioma Competitive Landscape 2023" report provides comprehensive insights about 200+ Glioma companies and 220+ drugs in Glioma Competitive landscape. It covers the Glioma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Glioma Competitive Landscape Report
• DelveInsight's Glioma report depicts a robust space with 200+ Glioma companies working to develop 220+ pipeline therapies…
Low-Grade Glioma Therapeutics Market - Transforming Futures, Defying Low-Grade G …
Newark, New Castle, USA - The latest report from Growth Plus Reports analyzes the production, potential applications, demand, major manufacturers, and SWOT analysis of the global Low-Grade Glioma Therapeutics Market.
Low-Grade Glioma Therapeutics Market: https://www.growthplusreports.com/report/lowgrade-glioma-therapeutics-market/9187
The Low-Grade Glioma Therapeutics Market Report assists in determining the optimum distribution methods for certain products as well as possible markets for future product launches. The report also analyses the purchase and supply trends that influence the…
Adult Malignant Glioma Therapeutics Market - Defying the Tumor, Empowering Survi …
Newark, New Castle, USA - new report, titled Adult Malignant Glioma Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Adult Malignant Glioma Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Adult Malignant Glioma Therapeutics market. The report offers…
Glioma pipeline involves 150+ key companies continuously working towards develop …
DelveInsight's, "Glioma Pipeline Insight, 2023," report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in Glioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Glioma Pipeline Report
• DelveInsight's glioma pipeline report depicts a…
Rising Number of People Diagnosed with Malignant Glioma Supports the Growth of t …
Glioma is a type of tumor that occurs in brain or spine. It is a group of brain tumor that includes oligodendrogliomas and astrocytomas. Gliomas include all types of brain tumors arising from supportive tissue of the brain. Malignant glioma is the most common type of brain tumor observed in adults globally. Collectively they contribute around 40% of the total cases diagnosed with brain tumor. In the last decade, there…
